Clinicopathological Characterization of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Anticancer Res. 2022 Nov;42(11):5601-5608. doi: 10.21873/anticanres.16068.

Abstract

Background/aim: Primary central nervous system diffuse large B-cell lymphoma (CNS DLBCL) is a rare entity, accounting for 3-4% of intracranial neoplasms. This study aimed to investigate the clinicopathological characteristics of primary CNS DLBCL patients and their prognostic implication.

Patients and methods: We collected 74 cases of clinically and pathologically confirmed primary CNS DLBCL from two institutions. Disease-free survival (DFS) and overall survival (OS) were analyzed based on various clinicopathological parameters.

Results: Most cases (83.8%) were classified as activated B-cell immunophenotype by Hans algorithm and cell-of-origin classification did not influence the clinical outcome. On univariate analysis, age (>60 years) and ECOG performance status (≥2) were significantly associated with shorter DFS and OS, and MYC/BCL2 co-expression significantly impacted poor DFS. An anaplastic variant was diagnosed in only 2 cases, but it raised possible association with poor outcome. On multivariate analysis, ECOG performance status and age was associated with poor prognosis.

Conclusion: In primary CNS DLBCL, age and performance status revealed the most significant association with prognosis. Cell-of-origin classification was not a significant prognostic factor in contrast to systemic DLBCL.

Keywords: Central nervous system; brain; lymphoma.

MeSH terms

  • Central Nervous System
  • Central Nervous System Neoplasms* / pathology
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Middle Aged
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-myc / genetics

Substances

  • Proto-Oncogene Proteins c-myc
  • Proto-Oncogene Proteins c-bcl-2